Physician profile
Michael S Haverty
NPI 1235114729
$11,748.28
in general payments reported to CMS, 2019-2025
44 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,514 · 2020: $2,046 · 2021: $2,740 · 2022: $1,836 · 2023: $1,267 · 2024: $1,279 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,772.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,225.74 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,044.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $954.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $874.56 | 2019-2025 | |
| Amgen INC. | $730.47 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $719.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $520.23 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $478.43 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.90 | 2020-2025 | Trintellix |
| Mylan Specialty L.P. | $420.26 | 2019-2024 | Yupelri |
| Exact Sciences Corporation | $250.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $228.97 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.59 | 2022-2025 | |
| Allergan, INC. | $209.84 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Haverty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.